JG
SMMT icon

Jain Global’s Summit Therapeutics SMMT Stock Holding History

Jain Global’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$205K Buy
+10,786
New +$174K ﹤0.01% 1087
2025
Q3 		– Sell
-87,943
Closed -$1.87M – 1455
2025
Q2 		$1.87M Buy
+87,943
New +$2.01M 0.01% 517

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jain Global's SMMT Position: Q1 2026 in Review

Jain Global opened a new position in Summit Therapeutics (SMMT) in Q1 2026: 10,786 shares worth $205K. The stake represents ﹤0.01% of the portfolio and ranks #1087 among its holdings. This is a return to the name: Jain Global previously reported a position in SMMT as recently as Q2 2025.

Jain Global first reported a position in SMMT in Q2 2025 and has held it in 2 quarters since. The position peaked at $1.87M in Q2 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Jain Global held 10,786 shares of Summit Therapeutics worth $205K as of Q1 2026.
  • Summit Therapeutics was a new Jain Global position in Q1 2026.
  • Summit Therapeutics made up ﹤0.01% of Jain Global's portfolio in Q1 2026, its #1087 holding.
  • Jain Global first reported a position in Summit Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Jain Global's Summit Therapeutics position peaked at $1.87M in Q2 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Jain Global's 13F filing for Q1 2026, filed 15 May 2026.